Department of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany.
Int J Mol Sci. 2024 May 21;25(11):5593. doi: 10.3390/ijms25115593.
The kinetics and mechanism of drug binding to its target are critical to pharmacological efficacy. A high throughput (HTS) screen often results in hundreds of hits, of which usually only simple IC values are determined during reconfirmation. However, kinetic parameters such as residence time for reversible inhibitors and the / ratio, which is the critical measure for evaluating covalent inactivators, are early predictive measures to assess the chances of success of the hits in the clinic. Using the promising cancer target human histone deacetylase 8 as an example, we present a robust method that calculates concentration-dependent apparent rate constants for the inhibition or inactivation of HDAC8 from dose-response curves recorded after different pre-incubation times. With these data, hit compounds can be classified according to their mechanism of action, and the relevant kinetic parameters can be calculated in a highly parallel fashion. HDAC8 inhibitors with known modes of action were correctly assigned to their mechanism, and the binding mechanisms of some hits from an internal HDAC8 screening campaign were newly determined. The oxonitriles SVE04 and SVE27 were classified as fast reversible HDAC8 inhibitors with moderate time-constant IC values of 4.2 and 2.6 µM, respectively. The hit compound TJ-19-24 and SAH03 behave like slow two-step inactivators or reversible inhibitors, with a very low reverse isomerization rate.
药物与靶标的结合动力学和机制对于药理学疗效至关重要。高通量 (HTS) 筛选通常会产生数百个命中物,其中通常仅在重新确证期间确定简单的 IC 值。然而,动力学参数,如可逆抑制剂的停留时间和 / 比值,是评估共价失活剂的关键指标,是评估命中物在临床成功机会的早期预测指标。以有前途的癌症靶标人组蛋白去乙酰化酶 8 为例,我们提出了一种稳健的方法,该方法可以从不同预孵育时间后记录的剂量反应曲线中计算出抑制或失活 HDAC8 的浓度依赖性表观速率常数。有了这些数据,就可以根据作用机制对命中化合物进行分类,并以高度并行的方式计算相关的动力学参数。具有已知作用模式的 HDAC8 抑制剂被正确分配到其作用机制中,并且还确定了内部 HDAC8 筛选活动中的一些命中化合物的结合机制。肟腈 SVE04 和 SVE27 被归类为快速可逆 HDAC8 抑制剂,其时间常数 IC 值分别为 4.2 和 2.6 µM。命中化合物 TJ-19-24 和 SAH03 表现为缓慢的两步失活剂或可逆抑制剂,其反向异构化速率非常低。